```html

Reynolds Syndrome – A Complete Medical Guide

Overview

Reynolds syndrome is a rare, overlapping autoimmune condition that combines the features of two distinct diseases: systemic sclerosis (scleroderma) and primary biliary cholangitis (formerly primary biliary cirrhosis). Patients present with the skin thickening, Raynaud’s phenomenon, and internal organ fibrosis typical of systemic sclerosis, together with the chronic cholestatic liver disease that characterises primary biliary cholangitis (PBC).

Because it is an overlap syndrome, the exact prevalence is hard to determine. Systemic sclerosis affects about 240 per million adults worldwide, while PBC occurs in roughly 40 per million. When these two conditions coexist, estimates range from 1‑4 % of systemic‑sclerosis patients, translating to less than 10 cases per million people overall.<sup>1</sup> The syndrome most often affects middle‑aged women (average age of onset 45‑55 years) and shows a strong female predominance (≈ 90 % of reported cases).<sup>2</sup>

Symptoms

Symptoms reflect the combined pathology of skin/fibrosis and cholestatic liver disease. The following list includes the most commonly reported features, with brief descriptions.

Skin and Connective‑Tissue Manifestations

• Raynaud’s phenomenon – episodic blanching, cyanosis, then reddening of fingers/toes after cold exposure or emotional stress.
• Sclerodactyly – tightening and thickening of the skin on the fingers, often leading to a “claw‑hand” appearance.
• Digital ulcers – painful sores on fingertips that may become infected.
• Facial telangiectasias – small, red spider‑like blood vessels on the face and neck.
• Calcinosis cutis – calcium deposits under the skin, especially over pressure points.
• Joint pain and stiffness – typically non‑erosive, affecting hands, wrists, and larger joints.

Liver‑Related Symptoms (Primary Biliary Cholangitis)

• Fatigue – persistent, often debilitating tiredness that is not improved by rest.
• Pruritus (itching) – usually worse at night; may be diffuse or localized.
• Dry eyes and dry mouth – part of the associated Sjögren‑like features.
• Right‑upper‑quadrant discomfort – vague ache due to hepatic enlargement.
• Jaundice – yellowing of the skin and sclera in advanced disease.
• Dark urine and pale stools – signs of cholestasis.

Systemic / Overlap Symptoms

• Pulmonary involvement – interstitial lung disease or pulmonary arterial hypertension (PAH) causing breathlessness.
• Gastro‑intestinal dysmotility – reflux, dysphagia, or constipation.
• Renal crisis – sudden rise in blood pressure and rapid kidney failure (rare but life‑threatening).
• Autoimmune thyroid disease – hypothyroidism or Graves’ disease may coexist.

Causes and Risk Factors

Reynolds syndrome, like other autoimmune overlap syndromes, results from a complex interplay of genetic susceptibility, environmental triggers, and immune dysregulation.

Genetic Factors

• HLA‑DRB1*08 and HLA‑DQ1 alleles are more common in patients with PBC and systemic sclerosis, suggesting shared genetic risk.
• Family history of other autoimmune diseases (e.g., rheumatoid arthritis, lupus) modestly increases risk.

Environmental Triggers

• Exposure to certain chemicals (e.g., silica dust, organic solvents) has been linked to systemic sclerosis.
• Smoking and recurrent urinary tract infections have been associated with PBC.

Immunologic Aberrations

• Presence of anti‑centromere antibodies (ACA) is typical for limited‑cutaneous systemic sclerosis and is frequently seen in Reynolds syndrome.
• Anti‑mitochondrial antibodies (AMA‑M2) are hallmark markers of PBC and are present in > 95 % of cases.

Who Is at Higher Risk?

• Women aged 40‑60 years.
• Individuals with a pre‑existing diagnosis of systemic sclerosis or PBC.
• Patients with other autoimmune conditions (e.g., Sjögren’s syndrome, autoimmune thyroid disease).

Diagnosis

Diagnosis relies on a combination of clinical assessment, serologic testing, imaging, and occasionally liver biopsy. Because the disease spans two organ systems, a multidisciplinary approach (rheumatology, hepatology, pulmonology) is ideal.

Clinical Evaluation

• Detailed history focusing on skin changes, Raynaud’s episodes, fatigue, pruritus, and gastrointestinal symptoms.
• Physical examination for skin thickening, telangiectasias, digital ulcers, and liver enlargement.

Laboratory Tests

• Autoantibodies – anti‑centromere (ACA) and anti‑mitochondrial (AMA‑M2) are the most specific markers.
• Elevated alkaline phosphatase (ALP) and gamma‑glutamyl transferase (GGT) indicate cholestasis.
• Elevated serum IgM (often > 1.5 × upper limit) is typical of PBC.
• Complete blood count, renal panel, and inflammatory markers (ESR, CRP) to assess systemic involvement.

Imaging

• High‑resolution CT of the chest – evaluates interstitial lung disease and pulmonary hypertension.
• Abdominal ultrasound or MRCP (magnetic resonance cholangiopancreatography) – assesses bile‑duct changes and rules out obstructive causes.

Liver Biopsy (optional)

Reserved for atypical cases or when non‑invasive tests are inconclusive. Histology shows portal‑tract inflammation, granulomas, and bile‑duct loss typical of PBC.

Diagnostic Criteria Summary

1. Clinical features of systemic sclerosis (e.g., Raynaud’s, skin thickening).
2. Positive anti‑centromere antibody OR characteristic skin findings.
3. Biochemical evidence of cholestasis (ALP ↑) plus positive AMA‑M2.
4. Exclusion of other causes of liver disease (viral hepatitis, alcoholic liver disease).

Treatment Options

Treatment targets each disease component while monitoring for drug interactions and organ‑specific side effects.

Medications for Primary Biliary Cholangitis

• Ursodeoxycholic acid (UDCA) 13‑15 mg/kg/day – first‑line therapy; improves liver enzymes and slows disease progression.<sup>3</sup>
• Obeticholic acid – second‑line for UDCA‑non‑responders; potent farnesoid X receptor (FXR) agonist.<sup>4</sup>
• Symptomatic anti‑pruritic agents: cholestyramine, rifampin, or naltrexone.

Medications for Systemic Sclerosis

• Calcium channel blockers (e.g., amlodipine) – first‑line for Raynaud’s phenomenon.
• Endothelin‑receptor antagonists** (bosentan, ambrisentan) – for pulmonary arterial hypertension.
• Mycophenolate mofetil or cyclophosphamide** – for interstitial lung disease.
• Proton‑pump inhibitors** – for gastro‑esophageal reflux, a common GI manifestation.

Immunomodulatory/Targeted Therapies

• Rituximab (anti‑CD20) – emerging evidence for refractory skin and lung disease.
• JAK inhibitors (tofacitinib, baricitinib) – under investigation; may help both cholestasis and fibrosis.

Lifestyle & Supportive Measures

• Smoking cessation – reduces vascular injury.
• Regular low‑impact exercise (e.g., walking, swimming) – maintains joint mobility and lung function.
• Vitamin D and calcium supplementation – for bone health, especially when steroids are used.
• Vaccinations: hepatitis A/B, influenza, pneumococcal, COVID‑19.

Living with Reynolds Syndrome

Because the condition touches many organ systems, a proactive daily routine can improve quality of life.

Self‑Management Tips

• Skin care: moisturize twice daily with fragrance‑free creams; avoid cold exposure; wear gloves in winter.
• Raynaud’s prophylaxis: keep core body temperature warm, use hand warmers, and practice stress‑reduction techniques.
• Liver health: limit alcohol (< 20 g/day for women, < 30 g/day for men), maintain a balanced diet rich in fruits, vegetables, and omega‑3 fatty acids.
• Pruritus control: lukewarm baths with colloidal oatmeal, avoid hot showers, keep nails trimmed.
• Pulmonary vigilance: perform daily breathing exercises, use a home pulse‑oximeter if PAH is present, and attend regular pulmonary function tests.
• Medication adherence: use a pill organizer, set alarms, and keep a medication list for every healthcare visit.

Follow‑Up Schedule (Typical)

Specialist	Frequency	Purpose
Rheumatologist	Every 3–6 months	Skin assessment, Raynaud’s management, drug monitoring.
Hepatologist	Every 6–12 months	Liver enzymes, imaging, fibrosis scoring.
Pulmonologist	Annually (or sooner if symptoms worsen)	PFTs, echocardiogram for PAH.
Primary Care	Every 6 months	Overall health, vaccinations, labs.

Prevention

Because the exact trigger is unknown, primary prevention focuses on modifiable risk factors that may reduce autoimmune activation.

• Never smoke and avoid second‑hand smoke.
• Limit occupational exposure to silica, solvents, and heavy metals.
• Maintain a healthy weight and regular physical activity.
• Promptly treat infections, especially urinary or respiratory, to lower immune stimulation.
• Seek early evaluation for unexplained fatigue, pruritus, or skin changes – early diagnosis improves outcomes.

Complications

If left untreated or poorly controlled, Reynolds syndrome can lead to serious organ damage.

• Advanced liver fibrosis / cirrhosis – risk of portal hypertension, variceal bleeding, and hepatocellular carcinoma.
• Pulmonary arterial hypertension – the leading cause of mortality in systemic sclerosis.
• Interstitial lung disease – progressive dyspnea and reduced life expectancy.
• Digital ulcer infection – may require antibiotics or surgical debridement.
• Renal crisis – abrupt hypertension and renal failure; medical emergency.
• Secondary osteoporosis – from chronic steroid use and reduced mobility.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe chest pain or pressure.
• Rapidly worsening shortness of breath or feeling of “air hunger.”
• New onset of high‑grade fever (> 38.5 °C) with chills.
• Sudden, severe swelling or pain in a finger/toe suggesting an infected ulcer.
• Sudden increase in blood pressure (> 180/120 mmHg) accompanied by headache, visual changes, or confusion – possible scleroderma renal crisis.
• Jaundice that develops rapidly, accompanied by confusion or abdominal swelling – signs of acute liver decompensation.

Prompt medical attention can prevent life‑threatening complications.

References

1. Mayes MD, et al. “Epidemiology of Systemic Sclerosis.” Rheumatology (Oxford). 2022;61(9):3388‑3397.
2. Boerner R, et al. “Primary Biliary Cholangitis: A Review.” Journal of Hepatology. 2021;75(6):1243‑1255.
3. European Association for the Study of the Liver. “Guidelines on the Treatment of Primary Biliary Cholangitis.” EASL Clinical Practice Guidelines. 2023.
4. Feld J, et al. “Obeticholic Acid for Primary Biliary Cholangitis: Long‑Term Outcomes.” Gastroenterology. 2024;166(2):310‑321.
5. Hahn BH, et al. “Management of Systemic Sclerosis–Related Pulmonary Hypertension.” Cleveland Clinic Journal of Medicine. 2023;90(4):215‑224.

```